Madhuri Gandikota is the Founder and CEO at Tapasvi Clin-MolBio Solutions Inc, a startup aiming to evaluate the vast amounts of clinical data with custom made analytics to increase the knowledge of all the stakeholders in the health care continuum. She has previously worked at UCSF and Stanford University, Amgen and Kriger Research Group International. She holds a Master's degree & Ph.D. in Life Sciences and a Post Doc in Molecular Biology & miRNA. She is a 2015 Fellow in the Startup Leadership Program in Silicon Valley.

Fellow since

Rachel Senturia is the Founder and CEO of STEMsocks, a startup aiming to celebrate science, promote a more modern version of science, and encourage scientific literacy, one totally rad sock at a time. She also works as an Intellectual Property Manager at Clontech. Prior to STEMsocks, she worked at Cellular & Research and Wilson Sonsini Goodrich & Rosati as a Patent Agent. She is an expert in Molecular Biology & Biochemistry. She holds a degree in Biochemistry and a Ph.D. in Biological Chemistry. She is a 2015 Fellow in the Startup Leadership Program in Silicon Valley.

Fellow since

Shalabh Gupta, Founder & CEO, Biocycive Shalabh Gupta, is Founder & CEO of BioCycive, Inc, a biotech company focused on developing new drugs in niche therapeutic indications, with a world-class scientific advisors, board members and strategic partners. Shalabh also serves on the board of directors of Phenomenome Discoveries, Inc, a diagnostic and therapeutics company backed by Canadian pension and PE funds. Earlier, Shalabh worked in Genentech, Inc. where he marketed Rituxan and Actemra, and worked on pipeline products. Prior to joining Genentech, he worked in equity research covering large-cap pharmaceutical companies at UBS and Rodman & Renshaw. He also served as an advisor to Green Hills Ventures, an early-stage private equity fund based in New York, where he managed the life-sciences portfolio for the fund. Shalabh was an attending physician and completed his MD at the NYU Medical Center and Rusk Institute of Rehabilitation Medicine. He has written and presented more than two dozen papers focused in the field of cardiac and pulmonary rehabilitation, and coordinated phase III and IV clinical trials at the NYU Medical Center. He was President of the national organization overseeing the 1500-strong rehabilitation resident physicians across the United States. Shalabh is a board certified physician with the American Board of Physical Medicine & Rehabilitation. He also received his Masters in Public Administration in health management from the Wagner School of Public Services at NYU. While in investment banking, he also held Series 7, 63, 86, and 87 securities licenses.

Fellow since

Shilpa Sambashivan is a scientist at Amgen Inc. Before Amgen, she worked at NGM Biopharmaceuticals Inc., a biotech startup dedicated to the development of novel therapeutics for Type 2 diabetes and related metabolic diseases. At NGM, Shilpa’s research was focused on the discovery, production and characterization of biologics that may play a role in regulating glucose homeostasis. Prior to NGM, Shilpa was a Postdoctoral fellow at Stanford University where she was awarded independent funding by the Bio-X program to carry out research in the area of protein misfolding and misfolding diseases. Shilpa received her PhD. from the University of California at Los Angeles in the field of molecular biology with an emphasis on structural biology. Shilpa’s research on the molecular basis of amyloid diseases resulted in two first author publications in Nature magazine and a dissertation award from the MBIDP program at UCLA. She received her undergraduate degree from the Birla Institute of Technology and Science, Pilani, India.

Fellow since